Machine learning predicted fast progression after initiation of immune checkpoint inhibitors in advanced non-small cell lung cancer.
作者信息
Soon Yu Yang, Tan Teng Hwee, Lee Chee Khoon, Stockler Martin
机构信息
Radiation Oncology, National University Cancer Institute, Singapore.
National University of Singapore, Singapore.
出版信息
BMJ Oncol. 2024 Feb 1;3(1):e000227. doi: 10.1136/bmjonc-2023-000227. eCollection 2024.
Abstract
摘要
相似文献
1
Machine learning predicted fast progression after initiation of immune checkpoint inhibitors in advanced non-small cell lung cancer.机器学习预测晚期非小细胞肺癌患者在开始使用免疫检查点抑制剂后的快速进展。
BMJ Oncol. 2024 Feb 1;3(1):e000227. doi: 10.1136/bmjonc-2023-000227. eCollection 2024.
2
Incidence of safety events after immune checkpoint inhibitor initiation for advanced-stage non-small-cell lung cancer: a real-world study.免疫检查点抑制剂治疗晚期非小细胞肺癌后安全性事件的发生率：一项真实世界研究。
Future Oncol. 2022 Aug;18(26):2891-2901. doi: 10.2217/fon-2022-0308. Epub 2022 Jul 18.
3
Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: a retrospective study.淋巴细胞亚群与晚期非小细胞肺癌免疫检查点抑制剂治疗疗效和预后的相关性：一项回顾性研究。
BMC Pulm Med. 2022 Apr 28;22(1):166. doi: 10.1186/s12890-022-01951-x.
4
Automatic machine learning accurately predicts the efficacy of immunotherapy for patients with inoperable advanced non-small cell lung cancer using a computed tomography-based radiomics model.自动机器学习使用基于计算机断层扫描的放射组学模型，准确预测不可切除的晚期非小细胞肺癌患者免疫治疗的疗效。
Diagn Interv Radiol. 2025 Mar 3;31(2):130-140. doi: 10.4274/dir.2024.242972. Epub 2025 Jan 16.
5
Excess weight and anti-PD-1 immune checkpoint inhibitor's outcomes in non-small cell lung cancer.超重与非小细胞肺癌抗 PD-1 免疫检查点抑制剂的疗效。
Clin Transl Oncol. 2022 Nov;24(11):2241-2249. doi: 10.1007/s12094-022-02887-8. Epub 2022 Jul 23.
6
Immune checkpoint inhibitors in advanced non-small cell lung cancer.免疫检查点抑制剂在晚期非小细胞肺癌中的应用。
Cancer. 2018 Jan 15;124(2):248-261. doi: 10.1002/cncr.31105. Epub 2017 Dec 6.
7
Machine learning analysis of pathological images to predict 1-year progression-free survival of immunotherapy in patients with small-cell lung cancer.机器学习分析病理图像预测小细胞肺癌患者免疫治疗 1 年无进展生存率
J Immunother Cancer. 2024 Feb 15;12(2):e007987. doi: 10.1136/jitc-2023-007987.
8
Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.免疫检查点阻断作为非小细胞肺癌的潜在治疗靶点。
Expert Opin Biol Ther. 2016 Oct;16(10):1209-23. doi: 10.1080/14712598.2016.1214265. Epub 2016 Aug 5.
9
Biomarkers of immunotherapy for non-small cell lung cancer.免疫治疗非小细胞肺癌的生物标志物。
Jpn J Clin Oncol. 2024 Jan 7;54(1):13-22. doi: 10.1093/jjco/hyad134.
10
deletion enhances the efficiency of immunotherapy in non-small-cell lung cancer.缺失增强了非小细胞肺癌的免疫疗法效率。
Bioengineered. 2022 May;13(5):11577-11592. doi: 10.1080/21655979.2022.2069328.
本文引用的文献
1
Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline.无驱动基因改变的IV期非小细胞肺癌的治疗：美国临床肿瘤学会生存指南
J Clin Oncol. 2022 Oct 1;40(28):3323-3343. doi: 10.1200/JCO.22.00825. Epub 2022 Jul 11.
2
Pre- and on-treatment lactate dehydrogenase as a prognostic and predictive biomarker in advanced non-small cell lung cancer.治疗前和治疗中乳酸脱氢酶作为晚期非小细胞肺癌的预后和预测生物标志物。
Cancer. 2022 Apr 15;128(8):1574-1583. doi: 10.1002/cncr.34113. Epub 2022 Jan 28.
3
Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non-Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or Chemotherapy.PD-1/PD-L1抑制剂或化疗治疗的晚期非小细胞肺癌中快速进展、超进展性疾病和早期死亡的比较
JCO Precis Oncol. 2020 Nov;4:829-840. doi: 10.1200/PO.20.00021.
4
Fast progression in non-small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel.非小细胞肺癌的快速进展：来自随机 III 期 OAK 研究的结果，评估二线阿特珠单抗对比多西他赛。
J Immunother Cancer. 2021 Mar;9(3). doi: 10.1136/jitc-2020-001882.
5
System for High-Intensity Evaluation During Radiation Therapy (SHIELD-RT): A Prospective Randomized Study of Machine Learning-Directed Clinical Evaluations During Radiation and Chemoradiation.用于放射治疗期间高强度评估的系统（SHIELD-RT）：放射治疗和放化疗期间机器学习指导的临床评估的前瞻性随机研究。
J Clin Oncol. 2020 Nov 1;38(31):3652-3661. doi: 10.1200/JCO.20.01688. Epub 2020 Sep 4.
6
Predicting Emergency Visits and Hospital Admissions During Radiation and Chemoradiation: An Internally Validated Pretreatment Machine Learning Algorithm.预测放疗和放化疗期间的急诊就诊和住院情况：一种经过内部验证的预处理机器学习算法。
JCO Clin Cancer Inform. 2018 Dec;2:1-11. doi: 10.1200/CCI.18.00037.
7
Patterns of Response and Progression to Immunotherapy.免疫疗法的反应和进展模式。
Am Soc Clin Oncol Educ Book. 2018 May 23;38:169-178. doi: 10.1200/EDBK_200643.
8
FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLC.FIR：在 PD-L1 选择的 NSCLC 患者中进行的 Atezolizumab Ⅱ期开放标签研究的疗效、安全性和生物标志物分析。
J Thorac Oncol. 2018 Nov;13(11):1733-1742. doi: 10.1016/j.jtho.2018.05.004.
9
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).阿特珠单抗作为程序性死亡配体1筛选的晚期非小细胞肺癌患者一线或后续治疗的II期试验（BIRCH）
J Clin Oncol. 2017 Aug 20;35(24):2781-2789. doi: 10.1200/JCO.2016.71.9476. Epub 2017 Jun 13.
10
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.阿特珠单抗对比多西他赛用于既往治疗过的非小细胞肺癌患者（OAK）：一项3期、开放标签、多中心随机对照试验
Lancet. 2017 Jan 21;389(10066):255-265. doi: 10.1016/S0140-6736(16)32517-X. Epub 2016 Dec 13.
Zotero 插件